eFFECTOR Therapeutics (EFTR) Competitors $0.0002 0.00 (-50.00%) As of 07/17/2025 09:32 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsShort InterestTrendsBuy This Stock EFTR vs. HSTO, ONCSQ, PXMD, ATNFW, LBPSW, AEHAW, AIMDW, ALVOW, ACABW, and BFRIWShould you be buying eFFECTOR Therapeutics stock or one of its competitors? The main competitors of eFFECTOR Therapeutics include Histogen (HSTO), OncoSec Medical (ONCSQ), PaxMedica (PXMD), 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Aesther Healthcare Acquisition (AEHAW), Ainos (AIMDW), Alvotech (ALVOW), Atlantic Coastal Acquisition Corp. II (ACABW), and Biofrontera (BFRIW). These companies are all part of the "pharmaceutical products" industry. eFFECTOR Therapeutics vs. Its Competitors Histogen OncoSec Medical PaxMedica 180 Life Sciences 4D pharma Aesther Healthcare Acquisition Ainos Alvotech Atlantic Coastal Acquisition Corp. II Biofrontera Histogen (NASDAQ:HSTO) and eFFECTOR Therapeutics (NASDAQ:EFTR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, media sentiment, institutional ownership, earnings, profitability and analyst recommendations. Is HSTO or EFTR more profitable? Company Net Margins Return on Equity Return on Assets HistogenN/A N/A N/A eFFECTOR Therapeutics N/A N/A N/A Which has more risk & volatility, HSTO or EFTR? Histogen has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500. Comparatively, eFFECTOR Therapeutics has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500. Do institutionals & insiders believe in HSTO or EFTR? 57.7% of eFFECTOR Therapeutics shares are held by institutional investors. 3.3% of Histogen shares are held by company insiders. Comparatively, 4.7% of eFFECTOR Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has better earnings & valuation, HSTO or EFTR? Histogen has higher revenue and earnings than eFFECTOR Therapeutics. Histogen is trading at a lower price-to-earnings ratio than eFFECTOR Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHistogen$19K5.06-$10.62M-$2.81-0.01eFFECTOR TherapeuticsN/AN/A-$35.81M-$13.080.00 Does the media prefer HSTO or EFTR? In the previous week, Histogen's average media sentiment score of 0.00 equaled eFFECTOR Therapeutics'average media sentiment score. Company Overall Sentiment Histogen Neutral eFFECTOR Therapeutics Neutral SummaryHistogen beats eFFECTOR Therapeutics on 4 of the 7 factors compared between the two stocks. Get eFFECTOR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for EFTR and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EFTR vs. The Competition Export to ExcelMetriceFFECTOR TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1K$817.60M$5.55B$9.40BDividend YieldN/A4.84%3.75%4.03%P/E Ratio0.001.4128.0119.82Price / SalesN/A27.13432.8198.20Price / CashN/A19.5636.1658.27Price / Book0.006.878.125.65Net Income-$35.81M-$4.17M$3.25B$257.91M7 Day PerformanceN/A-0.12%1.68%3.38%1 Month PerformanceN/A1.85%7.30%11.11%1 Year PerformanceN/A4.45%32.89%18.99% eFFECTOR Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EFTReFFECTOR Therapeutics0.0726 of 5 stars$0.00-50.0%N/A-99.6%$1KN/A0.0010HSTOHistogenN/A$0.00flatN/A-89.8%$1K$19K0.0020ONCSQOncoSec MedicalN/AN/AN/AN/A$1KN/A0.0040PXMDPaxMedicaN/A$0.00flatN/AN/A$1KN/A0.002ATNFW180 Life SciencesN/A$0.01-4.8%N/A-15.6%$0.00N/A0.007LBPSW4D pharmaN/AN/AN/AN/A$0.00$522K0.00N/AAEHAWAesther Healthcare AcquisitionN/A$0.01flatN/AN/A$0.00N/A0.002Gap DownAIMDWAinosN/A$0.12+0.2%N/AN/A$0.00$106.21K0.0040ALVOWAlvotechN/A$1.93+1.6%N/A-33.7%$0.00$585.60M0.004Gap DownACABWAtlantic Coastal Acquisition Corp. IIN/A$0.02flatN/AN/A$0.00N/A0.0015BFRIWBiofronteraN/A$0.09-14.2%N/A+99.8%$0.00$38.00M0.0070Gap Down Related Companies and Tools Related Companies Histogen Alternatives OncoSec Medical Alternatives PaxMedica Alternatives 180 Life Sciences Alternatives 4D pharma Alternatives Aesther Healthcare Acquisition Alternatives Ainos Alternatives Alvotech Alternatives Atlantic Coastal Acquisition Corp. II Alternatives Biofrontera Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EFTR) was last updated on 7/19/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding eFFECTOR Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share eFFECTOR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EFTR Stock Alerts